Bio-Rad Launches Anti-Idiotypic Antibodies Targeting Pembrolizumab and Nivolumab
Anti-idiotypic antibodies will enable monitoring of for pembrolizumab and nivolumab levels in cancer patients undergoing treatment.
Read More
Search Results for: lung cancer
Predicting the Effectiveness of Anti-PD-L1 Therapy
A potential alternative to immunohistochemistry for predicting patients’ response to anti-PD-L1 therapy is to use testing based on the droplet digital polymerase chain reaction technique to detect changes in the mRNA expression levels in patients’ blood.
Read More
Liquid Biopsy Scores Immunotherapy Effectiveness
Circulating tumor DNA is a reliable biomarker of tumor progression following immunotherapy treatment.
Read MorePrognostic Information Provided by Biodesix Proteomic Test Alters Oncologists’ Treatment Decisions
A blood-based proteomic test reliably assesses individual patient prognosis to inform treatment decisions and reduce costs associated with overtreatment in lung cancer.
Read More
New Data Show Biodesix Blood Test Reliably Detects Additional Mutations in Patients with NSCLC
The highly multiplexed ddPCR-based assay is currently in use by biopharma partners.
Read More